PDE5 Inhibitors Are NOT Recommended for Pulmonary Hypertension Due to Pulmonary Fibrosis
For patients with pulmonary hypertension secondary to pulmonary fibrosis (WHO Group 3 PH), PDE5 inhibitors should not be used as standard treatment, as they provide no clear clinical benefit and are not supported by current guidelines.
Evidence-Based Rationale
Guideline Recommendations
The 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline specifically addressed sildenafil (a PDE5 inhibitor) in idiopathic pulmonary fibrosis 1. The STEP-IPF trial randomized 180 patients with advanced IPF to sildenafil versus placebo and found:
- No significant benefit on the primary outcome (6-minute walk distance improvement)
- Only small improvements in secondary outcomes (dyspnea, quality of life, DLCO)
- A predefined subgroup analysis suggested benefit only in the 119 patients with documented right ventricular systolic dysfunction on echocardiogram
The guideline concluded that sildenafil showed no meaningful benefit for the general IPF population 1.
Supporting Research Evidence
The most recent and highest-quality evidence comes from a 2021 real-world study that evaluated sildenafil added to antifibrotic treatment in IPF patients 2. Using propensity score matching with 51 matched pairs:
- No difference in FVC decline rate (-101 mL/year vs -117 mL/year, p=0.714)
- No impact on all-cause mortality, hospitalization, or acute exacerbation in multivariable analyses
- This held true even when adjusted for presence of pulmonary hypertension
A 2019 Cochrane systematic review examining PDE5 inhibitors across all PH groups found 3:
- Clear benefits in WHO Group 1 PAH (pulmonary arterial hypertension)
- No clear benefit for PH secondary to lung disease (Group 3)
- Low-quality evidence due to imprecision and inconsistency across trials
- Only a small 27-meter improvement in 6MWD, which is not clinically meaningful
Clinical Context: WHO Group Classification Matters
The 2015 ESC/ERS Guidelines provide treatment algorithms specifically for Group 1 PAH only 4. These guidelines explicitly state that their treatment recommendations, including PDE5 inhibitors, apply to pulmonary arterial hypertension—not to PH secondary to lung disease (Group 3).
Key Distinction:
- Group 1 PAH: PDE5 inhibitors are recommended with high-certainty evidence
- Group 3 PH (lung disease/hypoxia): No established benefit, different pathophysiology
Common Pitfalls to Avoid
Do not extrapolate Group 1 PAH data to Group 3 PH: The underlying mechanisms differ fundamentally. Group 3 PH is primarily driven by hypoxic vasoconstriction and parenchymal lung destruction, not the proliferative vasculopathy seen in PAH.
Possible exception—severe PH with PVR >5 Wood units: While not standard, some emerging data suggest potential benefit in COPD patients with severe PH (PVR >5 WU) 5. However, this evidence is from COPD specifically, not interstitial lung disease/pulmonary fibrosis, and requires further validation.
Right ventricular dysfunction subgroup: The STEP-IPF subgroup analysis suggested benefit in patients with documented RV dysfunction 1, but this was a post-hoc analysis and has not been validated in subsequent trials.
Practical Approach
For patients with pulmonary fibrosis and PH:
- Focus on treating the underlying lung disease with antifibrotic agents (pirfenidone or nintedanib)
- Optimize oxygen therapy to prevent hypoxic vasoconstriction
- Consider lung transplantation evaluation for appropriate candidates
- Reserve PDE5 inhibitors only for highly selected cases with severe, out-of-proportion PH (PVR >5 WU) documented by right heart catheterization, and only after expert consultation
- Do not use PDE5 inhibitors routinely based solely on echocardiographic estimates of pulmonary pressures